DRMA Dermata Therapeutics, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1853816 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-7.4%
TTM EPS YoY-121.6%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-241.5%
ROA-162.3%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets41.1%
Debt / equity0.00x
Current ratio—
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.93x
Accruals ratio-10.6%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | — | — | — | — | — |
| R&D expense | $2.93M | $8.20M | $4.07M | $5.65M | $3.46M |
| SG&A expense | $4.84M | $4.31M | $3.97M | $4.02M | $4.40M |
| Operating income | -$7.77M | -$12.51M | -$8.04M | -$9.67M | -$7.86M |
| Interest expense | — | — | — | — | $45,613 |
| Income tax | — | $0 | $0 | $0 | $0 |
| Net income | -$7.56M | -$12.29M | -$7.79M | -$9.61M | -$7.90M |
| EBITDA | — | — | — | — | -$7.86M |
| EPS (basic) | -8.16 | -80.32 | -39.99 | -13.92 | -2.43 |
| EPS (diluted) | -8.16 | -80.32 | -39.99 | — | — |
| Weighted avg. shares (diluted) | 926,192 | 152,974 | 194,928 | — | — |
| Banking | |||||
| Net interest income | — | — | — | $63,573 | -$45,613 |
| Balance sheet | |||||
| Cash & equivalents | $7.52M | $3.16M | $7.44M | $6.24M | $10.80M |
| Current assets | $7.86M | — | — | — | $11.62M |
| PP&E, net | — | — | — | — | $0 |
| Total assets | $7.86M | $3.53M | $7.98M | $6.94M | $11.62M |
| Current liabilities | — | — | — | — | $1.52M |
| Short-term debt | — | — | — | — | $0 |
| Total liabilities | $1.64M | $1.97M | $1.62M | $922,634 | $1.52M |
| Shareholders' equity | $6.22M | $1.56M | $6.36M | $6.02M | $10.11M |
| Shares outstanding | 2.66M | 251,725 | 261,998 | 770,115 | 8.33M |
| Cash flow statement | |||||
| Operating cash flow | -$7.76M | -$11.16M | -$6.41M | -$8.83M | -$5.69M |
| Financing cash flow | $12.12M | $6.89M | $7.61M | $4.28M | $15.96M |
| Depreciation & amortization | — | — | — | — | $0 |
| Stock-based compensation | $143,732 | $657,649 | $522,082 | $930,325 | $1.91M |
Free plan shows the latest 5 periods; Pro shows all 6 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.